Rocket Pharmaceuticals (RCKT) PT Lowered to $34 at Goldman Sachs
Tweet
Share
E-mailGet Alerts RCKT Hot Sheet
Price: $3.40 --0%
Rating Summary:
15 Buy, 7 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 8 | New: 13
Rating Summary:
15 Buy, 7 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 8 | New: 13
Join SI Premium – FREE
Goldman Sachs analyst Richard Law lowered the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $34.00 (from $39.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Berenberg Downgrades PolyPeptide Group AG (PPGN:SW) to Hold
- Talanx (TLX:GR) (TNXXF) PT Raised to EUR163 at Berenberg
- HA Sustainable Infrastructure Ca (HASI) PT Lowered to $45 at BofA Securities
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
